SCIENCE AT THE SPEED OF BUSINESS

Our fundamental premise is that innovative methods, analytical rigor, and scientific acumen can be provided in a commercial entity that operates “at the speed of business.” Monument Analytics delivers.

Unparalleled Knowledge Base

One of the most remarkable features of Monument Analytics is its access to consultants with an unparalleled knowledge base. Through its independent consulting services, Monument Analytics leverages this acumen to assist clients developing products and services for the benefit of society.

Top Notch Evidence

By capitalizing on this unparalleled depth and breadth of human capital, Monument Analytics is able to generate the highest quality evidence regarding the safety, effectiveness, and real-world value of the full range of medical processes and technologies; and to use this knowledge to help our clients navigate evermore complex and challenging regulatory and payment environments.

Internationally Renowned Experts

Our Principals and Consultants are internationally renowned for their expertise in areas ranging from epidemiology and biostatistics to clinical fields such as cardiovascular medicine, oncology, and immunology.

G. Caleb Alexander
G. Caleb AlexanderMD, MS
CO-FOUNDER & PRINCIPAL
Jonothan C. Tierce
Jonothan C. TierceCPhil
CO-FOUNDER & PRINCIPAL
William V. Padula
William V. PadulaPhD
PRINCIPAL
Natalie Reid
Natalie ReidPhD, MPH, MBA
DIRECTOR
MEET THE CONSULTING TEAM

Services

Our services are broadly organized into four core capabilities

  • Comparative effectiveness analyses
  • Pharmacovigilance and safety assessments
  • Investigations of drug utilization
  • Risk-benefit appraisals
  • Bayesian, meta-analytic and systematic reviews
  • Patient and clinician preferences
  • Global marketplace and pharmaceutical policy
  • Design and conduct of sophisticated comparative effectiveness, pharmacovigilance, and drug utilization studies
  • Advanced techniques for causal inference, management of missing data, and other statistical analysis
  • Cost-benefit analysis and cost-effectiveness analysis
  • Natural history of disease and resource utilization
  • Systematic economic and quality-of-life reviews
  • Core value dossiers

MA in the News

July 9, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander co-authored a JAMA Health Forum article titled: “Changes in Short-term, Long-term, and Preventive Care Delivery in US Office-Based and Telemedicine Visits During the COVID-19 Pandemic.” The article received media attention in an article from EurekAlert! titled: “Changes in care delivery during COVID-19.”

June 29, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was featured in the Charleston Gazette-Mail article titled: “Opioid abatement plan will cost $2.54 billion for Huntington, Cabell experts say” for his abatement plan expert testimony in the Huntington opioid trial.

June 28, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was featured in the Charleston Gazette-Mail article titled: “Proper funds, programs could reduce by half the local impact of the opioid crisis, expert says” for his abatement plan expert testimony in the Huntington opioid trial.

June 18, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was quoted in a KFGO article titled: “Analysis: Rival treatments may help justify FDA gamble with Biogen Alzheimer’s drug.” Dr. Alexander explained that the FDA approval of aducanumab is precedent-setting.

June 17, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander co-authored a piece in Annals of Internal Medicine titled: “The Problem of Aducanumab for the Treatment of Alzheimer Disease.” The piece received media attention in an EurekAlert! article titled: “FDA advisory panelist outlines issues with aducanumab’s approval for Alzheimer’s disease.”

June 7, 2021  Caleb Alexander
Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was the subject of The New York Times “Quotation of the Day: F.D.A. Approves New Medication for Alzheimer’s.” Dr. Alexander said, “There’s no way to recover the opportunity to understand whether or not the product really works in the post-approval setting.” about the FDA approval of aducanumab.

SEE ALL MA NEWS